Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top AIDS drugs worldwide based on revenue 2014-2017

Selected top AIDS drugs worldwide based on revenue from 2014 to 2017 (in million U.S. dollars)

by Matej Mikulic, last edited May 21, 2019
Top AIDS drugs worldwide based on revenue 2014-2017 Globally, the top drug for the treatment of human immunodeficiency virus (HIV) from 2014 to 2017 was Triumeq, marketed by GlaxoSmithKline. Triumeq generated an estimated 3.3 billion U.S. dollars in revenue. Truvada, marketed by Gilead, generated slightly less than Triumeq with 3.1 billion U.S. dollars in revenue. Triumeq and Truvada are both combination antiretroviral medications. Gilead Sciences and GlaxoSmithKline are among the drug manufacturers most specialized in developing drugs for the treatment of HIV/AIDS.
HIV/AIDS cases worldwide

HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Swaziland, followed by Lesotho had the highest rates of HIV infections in 2017. The number of new HIV infections yearly is highest among residents of South Africa.

Access to HIV/AIDS treatment

Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2017 there were almost 22 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS. Meanwhile, trends indicate that children living with HIV in Asia or the Pacific have some of the highest rates of access to antiretroviral therapy globally.
Show more

Selected top AIDS drugs worldwide based on revenue from 2014 to 2017 (in million U.S. dollars)

2014201520162017
-----
-----
-----
-----
-----
-----
-----
-----
-----
-----
-----
2014201520162017
-----
-----
-----
-----
-----
-----
-----
-----
-----
-----
-----
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Matej Mikulic, last edited May 21, 2019
Globally, the top drug for the treatment of human immunodeficiency virus (HIV) from 2014 to 2017 was Triumeq, marketed by GlaxoSmithKline. Triumeq generated an estimated 3.3 billion U.S. dollars in revenue. Truvada, marketed by Gilead, generated slightly less than Triumeq with 3.1 billion U.S. dollars in revenue. Triumeq and Truvada are both combination antiretroviral medications. Gilead Sciences and GlaxoSmithKline are among the drug manufacturers most specialized in developing drugs for the treatment of HIV/AIDS.
HIV/AIDS cases worldwide

HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Swaziland, followed by Lesotho had the highest rates of HIV infections in 2017. The number of new HIV infections yearly is highest among residents of South Africa.

Access to HIV/AIDS treatment

Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2017 there were almost 22 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS. Meanwhile, trends indicate that children living with HIV in Asia or the Pacific have some of the highest rates of access to antiretroviral therapy globally.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Global HIV/AIDS epidemic
Global HIV/AIDS epidemic

All Information
in one Presentation

Global HIV/AIDS epidemic

Everything On "Global HIV/AIDS epidemic" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Global HIV/AIDS epidemic"
  • Overview
  • Prevalence
  • Other HIV figures
  • AIDS deaths
  • Spending/funding
  • Treatment
The most important statistics
  • HIV and tuberculosis
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.